Look up one drug

Ontario coverage, price, criteria word for word, Health Canada status and shortages for one product

Patient plan: look up a medication list

Showing products 1–24 of 36. More products

CELECOXIB

All strengths: Limited Use — Reason for Use code 316, 317 required; same patient cost rules

Shared coverage and patient cost rules
StatusLimited Use — Reason for Use code 316, 317 required
Patient paysPatient pays: program not supplied; amount cannot be determined.

Other products in the same Health Canada class (M01A) — coverage varies; not interchangeable

  • Diclofenac (Voltaren): general benefit, Not a benefit
  • Diclofenac + misoprostol (Arthrotec 50): general benefit
  • Flurbiprofen (Ansaid): general benefit, Not a benefit
  • Ibuprofen (Motrin): general benefit, Not a benefit
  • Indomethacin (Indocid): general benefit, Not a benefit
  • Ketoprofen (Ketoprofen): general benefit, Not a benefit

12 more in the class list below

AG-Celecoxib · DIN 02437570 · 100mg · capsule

Limited Use — Reason for Use code 316, 317 requiredMarketed · checked 2026-09-02
Write on scriptLU code 316, 317 (patient must meet the criteria below)
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Ontario Limited Use criteria — code 316, 317
Coverage limit: Osteoarthritis Reason for Use code 316 For patients who have failed an adequate trial of acetaminophen (e.g. acetaminophen 1g QID for several weeks) and have had: Coverage limit: History of a documented, clinically significant ulcer or GI bleed; or Failure or intolerance to at least three listed NSAIDS. Coverage limit: The maximum daily dose of celecoxib which will be reimbursed for the treatment of osteoarthritis is 200mg. Coverage limit: LU Authorization Period: 1 year Coverage limit: Rheumatoid arthritis Reason for Use code 317 For patients who have had: Coverage limit: History of a documented, clinically significant ulcer or GI bleed; or Failure or intolerance to at least three listed NSAIDS. Coverage limit: The maximum daily dose of celecoxib which will be reimbursed for the treatment of rheumatoid arthritis is 400mg. Coverage limit: LU Authorization Period: 1 year
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
AG-Celecoxib · DIN 02437570 Manufacturer: Angita Pharma Inc.; listing date 2020-11-30 Health Canada: Marketed since 2019-05-13 · brand AG-CELECOXIB · ATC M01AH01 CELECOXIB · form Capsule · route Oral · ingredients CELECOXIB 100 MG · company Angita pharma inc. · schedule Prescription
Check this DIN again · Health Canada product record

AG-Celecoxib: Formulary list price $0.1279/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.1279 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=92190 · Verify on the e-Formulary ↗ (DIN 02437570)

Source record
DIN 02437570: AG-Celecoxib Raw flags: sec12=Y, sec3=Y Item: 280804075; group id 377; item number 0898; lccId 00064; manufacturer id ANG Source form: Cap; strength: 100mg Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below Source prices (unrounded): $0.1279; ministry $0.1279 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02437570 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=92190 Therapeutic Notes (formulary) NSAIDs have a high rate of serious adverse effects in the elderly. When prescribing NSAIDs, the minimal effective dose for the shortest period of time should be used. In nonspecific pain and/or osteoarthritis, in the absence of joint inflammation (swelling), acetaminophen is a better first choice for analgesia. The most effective treatment to prevent NSAID-gastritis is misoprostol; although H-2 antagonists, such as ranitidine or cimetidine, are commonly used, they are not as effective. NSAIDs can significantly aggravate hypertension and congestive heart failure; ASA in doses below 1 gram per day is a better choice than other NSAID options if anti-inflammatory effects are required in patients with these conditions. Low dose ASA has additional benefits for anti-platelet indications that are not provided by other NSAIDs, and should be given in preference or in addition to other NSAIDs for patients with vascular indications.
Interchangeable products
Act Celecoxib · DIN 02420155 · $0.1279 Apo-Celecoxib · DIN 02418932 · $0.1279 Auro-Celecoxib · DIN 02445670 · $0.1279 Bio-Celecoxib · DIN 02426382 · $0.1279 Celebrex · DIN 02239941 · $0.1279 Celecoxib · DIN 02429675 · $0.1279 Celecoxib · DIN 02436299 · $0.1279 Jamp-Celecoxib · DIN 02424533 · $0.1279 M-Celecoxib · DIN 02495465 · $0.1279 Mar-Celecoxib · DIN 02420058 · $0.1279 Mint-Celecoxib · DIN 02412497 · $0.1279 NRA-Celecoxib · DIN 02479737 · $0.1279 PMS-Celecoxib · DIN 02355442 · $0.1279 PMSC-Celecoxib · DIN 02517116 · $0.1279 Ran-Celecoxib · DIN 02412373 · $0.1279 Sdz Celecoxib · DIN 02442639 · $0.1279 Teva-Celecoxib · DIN 02288915 · $0.1279
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02437570
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Apo-Celecoxib · DIN 02418932 · 100mg · capsule

Limited Use — Reason for Use code 316, 317 requiredMarketed · checked 2026-09-02
Write on scriptLU code 316, 317 (patient must meet the criteria below)
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Ontario Limited Use criteria — code 316, 317
Coverage limit: Osteoarthritis Reason for Use code 316 For patients who have failed an adequate trial of acetaminophen (e.g. acetaminophen 1g QID for several weeks) and have had: Coverage limit: History of a documented, clinically significant ulcer or GI bleed; or Failure or intolerance to at least three listed NSAIDS. Coverage limit: The maximum daily dose of celecoxib which will be reimbursed for the treatment of osteoarthritis is 200mg. Coverage limit: LU Authorization Period: 1 year Coverage limit: Rheumatoid arthritis Reason for Use code 317 For patients who have had: Coverage limit: History of a documented, clinically significant ulcer or GI bleed; or Failure or intolerance to at least three listed NSAIDS. Coverage limit: The maximum daily dose of celecoxib which will be reimbursed for the treatment of rheumatoid arthritis is 400mg. Coverage limit: LU Authorization Period: 1 year
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Apo-Celecoxib · DIN 02418932 Manufacturer: Apotex Inc.; listing date 2015-01-28 Health Canada: Marketed since 2014-11-17 · brand APO-CELECOXIB · ATC M01AH01 CELECOXIB · form Capsule · route Oral · ingredients CELECOXIB 100 MG · company Apotex inc · schedule Prescription
Check this DIN again · Health Canada product record

Apo-Celecoxib: Formulary list price $0.1279/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.1279 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=90347 · Verify on the e-Formulary ↗ (DIN 02418932)

Source record
DIN 02418932: Apo-Celecoxib Raw flags: sec12=Y, sec3=Y Item: 280804075; group id 377; item number 0898; lccId 00064; manufacturer id APX Source form: Cap; strength: 100mg Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below Source prices (unrounded): $0.1279; ministry $0.1279 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02418932 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=90347 Therapeutic Notes (formulary) NSAIDs have a high rate of serious adverse effects in the elderly. When prescribing NSAIDs, the minimal effective dose for the shortest period of time should be used. In nonspecific pain and/or osteoarthritis, in the absence of joint inflammation (swelling), acetaminophen is a better first choice for analgesia. The most effective treatment to prevent NSAID-gastritis is misoprostol; although H-2 antagonists, such as ranitidine or cimetidine, are commonly used, they are not as effective. NSAIDs can significantly aggravate hypertension and congestive heart failure; ASA in doses below 1 gram per day is a better choice than other NSAID options if anti-inflammatory effects are required in patients with these conditions. Low dose ASA has additional benefits for anti-platelet indications that are not provided by other NSAIDs, and should be given in preference or in addition to other NSAIDs for patients with vascular indications.
Interchangeable products
AG-Celecoxib · DIN 02437570 · $0.1279 Act Celecoxib · DIN 02420155 · $0.1279 Auro-Celecoxib · DIN 02445670 · $0.1279 Bio-Celecoxib · DIN 02426382 · $0.1279 Celebrex · DIN 02239941 · $0.1279 Celecoxib · DIN 02429675 · $0.1279 Celecoxib · DIN 02436299 · $0.1279 Jamp-Celecoxib · DIN 02424533 · $0.1279 M-Celecoxib · DIN 02495465 · $0.1279 Mar-Celecoxib · DIN 02420058 · $0.1279 Mint-Celecoxib · DIN 02412497 · $0.1279 NRA-Celecoxib · DIN 02479737 · $0.1279 PMS-Celecoxib · DIN 02355442 · $0.1279 PMSC-Celecoxib · DIN 02517116 · $0.1279 Ran-Celecoxib · DIN 02412373 · $0.1279 Sdz Celecoxib · DIN 02442639 · $0.1279 Teva-Celecoxib · DIN 02288915 · $0.1279
Shortage status: resolved shortage (ended 2025-01-23); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02418932
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Auro-Celecoxib · DIN 02445670 · 100mg · capsule

Limited Use — Reason for Use code 316, 317 requiredMarketed · checked 2026-09-02
Write on scriptLU code 316, 317 (patient must meet the criteria below)
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Ontario Limited Use criteria — code 316, 317
Coverage limit: Osteoarthritis Reason for Use code 316 For patients who have failed an adequate trial of acetaminophen (e.g. acetaminophen 1g QID for several weeks) and have had: Coverage limit: History of a documented, clinically significant ulcer or GI bleed; or Failure or intolerance to at least three listed NSAIDS. Coverage limit: The maximum daily dose of celecoxib which will be reimbursed for the treatment of osteoarthritis is 200mg. Coverage limit: LU Authorization Period: 1 year Coverage limit: Rheumatoid arthritis Reason for Use code 317 For patients who have had: Coverage limit: History of a documented, clinically significant ulcer or GI bleed; or Failure or intolerance to at least three listed NSAIDS. Coverage limit: The maximum daily dose of celecoxib which will be reimbursed for the treatment of rheumatoid arthritis is 400mg. Coverage limit: LU Authorization Period: 1 year
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Auro-Celecoxib · DIN 02445670 Manufacturer: Auro Pharma Inc.; listing date 2016-07-28 Health Canada: Marketed since 2015-12-02 · brand AURO-CELECOXIB · ATC M01AH01 CELECOXIB · form Capsule · route Oral · ingredients CELECOXIB 100 MG · company Auro pharma inc · schedule Prescription
Check this DIN again · Health Canada product record

Auro-Celecoxib: Formulary list price $0.1279/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.1279 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=93095 · Verify on the e-Formulary ↗ (DIN 02445670)

Source record
DIN 02445670: Auro-Celecoxib Raw flags: sec12=Y, sec3=Y Item: 280804075; group id 377; item number 0898; lccId 00064; manufacturer id AUR Source form: Cap; strength: 100mg Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below Source prices (unrounded): $0.1279; ministry $0.1279 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02445670 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=93095 Therapeutic Notes (formulary) NSAIDs have a high rate of serious adverse effects in the elderly. When prescribing NSAIDs, the minimal effective dose for the shortest period of time should be used. In nonspecific pain and/or osteoarthritis, in the absence of joint inflammation (swelling), acetaminophen is a better first choice for analgesia. The most effective treatment to prevent NSAID-gastritis is misoprostol; although H-2 antagonists, such as ranitidine or cimetidine, are commonly used, they are not as effective. NSAIDs can significantly aggravate hypertension and congestive heart failure; ASA in doses below 1 gram per day is a better choice than other NSAID options if anti-inflammatory effects are required in patients with these conditions. Low dose ASA has additional benefits for anti-platelet indications that are not provided by other NSAIDs, and should be given in preference or in addition to other NSAIDs for patients with vascular indications.
Interchangeable products
AG-Celecoxib · DIN 02437570 · $0.1279 Act Celecoxib · DIN 02420155 · $0.1279 Apo-Celecoxib · DIN 02418932 · $0.1279 Bio-Celecoxib · DIN 02426382 · $0.1279 Celebrex · DIN 02239941 · $0.1279 Celecoxib · DIN 02429675 · $0.1279 Celecoxib · DIN 02436299 · $0.1279 Jamp-Celecoxib · DIN 02424533 · $0.1279 M-Celecoxib · DIN 02495465 · $0.1279 Mar-Celecoxib · DIN 02420058 · $0.1279 Mint-Celecoxib · DIN 02412497 · $0.1279 NRA-Celecoxib · DIN 02479737 · $0.1279 PMS-Celecoxib · DIN 02355442 · $0.1279 PMSC-Celecoxib · DIN 02517116 · $0.1279 Ran-Celecoxib · DIN 02412373 · $0.1279 Sdz Celecoxib · DIN 02442639 · $0.1279 Teva-Celecoxib · DIN 02288915 · $0.1279
Shortage status: resolved shortage (ended 2025-06-01); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02445670
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Bio-Celecoxib · DIN 02426382 · 100mg · capsule

Limited Use — Reason for Use code 316, 317 requiredMarketed · checked 2026-09-02
Write on scriptLU code 316, 317 (patient must meet the criteria below)
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Ontario Limited Use criteria — code 316, 317
Coverage limit: Osteoarthritis Reason for Use code 316 For patients who have failed an adequate trial of acetaminophen (e.g. acetaminophen 1g QID for several weeks) and have had: Coverage limit: History of a documented, clinically significant ulcer or GI bleed; or Failure or intolerance to at least three listed NSAIDS. Coverage limit: The maximum daily dose of celecoxib which will be reimbursed for the treatment of osteoarthritis is 200mg. Coverage limit: LU Authorization Period: 1 year Coverage limit: Rheumatoid arthritis Reason for Use code 317 For patients who have had: Coverage limit: History of a documented, clinically significant ulcer or GI bleed; or Failure or intolerance to at least three listed NSAIDS. Coverage limit: The maximum daily dose of celecoxib which will be reimbursed for the treatment of rheumatoid arthritis is 400mg. Coverage limit: LU Authorization Period: 1 year
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Bio-Celecoxib · DIN 02426382 Manufacturer: Biomed Pharma; listing date 2016-02-25 Health Canada: Marketed since 2014-12-05 · brand BIO-CELECOXIB · ATC M01AH01 CELECOXIB · form Capsule · route Oral · ingredients CELECOXIB 100 MG · company Biomed pharma · schedule Prescription
Check this DIN again · Health Canada product record

Bio-Celecoxib: Formulary list price $0.1279/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.1279 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=91097 · Verify on the e-Formulary ↗ (DIN 02426382)

Source record
DIN 02426382: Bio-Celecoxib Raw flags: sec12=Y, sec3=Y Item: 280804075; group id 377; item number 0898; lccId 00064; manufacturer id BMP Source form: Cap; strength: 100mg Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below Source prices (unrounded): $0.1279; ministry $0.1279 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02426382 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=91097 Therapeutic Notes (formulary) NSAIDs have a high rate of serious adverse effects in the elderly. When prescribing NSAIDs, the minimal effective dose for the shortest period of time should be used. In nonspecific pain and/or osteoarthritis, in the absence of joint inflammation (swelling), acetaminophen is a better first choice for analgesia. The most effective treatment to prevent NSAID-gastritis is misoprostol; although H-2 antagonists, such as ranitidine or cimetidine, are commonly used, they are not as effective. NSAIDs can significantly aggravate hypertension and congestive heart failure; ASA in doses below 1 gram per day is a better choice than other NSAID options if anti-inflammatory effects are required in patients with these conditions. Low dose ASA has additional benefits for anti-platelet indications that are not provided by other NSAIDs, and should be given in preference or in addition to other NSAIDs for patients with vascular indications.
Interchangeable products
AG-Celecoxib · DIN 02437570 · $0.1279 Act Celecoxib · DIN 02420155 · $0.1279 Apo-Celecoxib · DIN 02418932 · $0.1279 Auro-Celecoxib · DIN 02445670 · $0.1279 Celebrex · DIN 02239941 · $0.1279 Celecoxib · DIN 02429675 · $0.1279 Celecoxib · DIN 02436299 · $0.1279 Jamp-Celecoxib · DIN 02424533 · $0.1279 M-Celecoxib · DIN 02495465 · $0.1279 Mar-Celecoxib · DIN 02420058 · $0.1279 Mint-Celecoxib · DIN 02412497 · $0.1279 NRA-Celecoxib · DIN 02479737 · $0.1279 PMS-Celecoxib · DIN 02355442 · $0.1279 PMSC-Celecoxib · DIN 02517116 · $0.1279 Ran-Celecoxib · DIN 02412373 · $0.1279 Sdz Celecoxib · DIN 02442639 · $0.1279 Teva-Celecoxib · DIN 02288915 · $0.1279
Shortage status: resolved shortage (ended 2019-07-20); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02426382
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Celebrex · DIN 02239941 · 100mg · capsule

Limited Use — Reason for Use code 316, 317 requiredMarketed · checked 2026-09-02
Write on scriptLU code 316, 317 (patient must meet the criteria below)
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Ontario Limited Use criteria — code 316, 317
Coverage limit: Osteoarthritis Reason for Use code 316 For patients who have failed an adequate trial of acetaminophen (e.g. acetaminophen 1g QID for several weeks) and have had: Coverage limit: History of a documented, clinically significant ulcer or GI bleed; or Failure or intolerance to at least three listed NSAIDS. Coverage limit: The maximum daily dose of celecoxib which will be reimbursed for the treatment of osteoarthritis is 200mg. Coverage limit: LU Authorization Period: 1 year Coverage limit: Rheumatoid arthritis Reason for Use code 317 For patients who have had: Coverage limit: History of a documented, clinically significant ulcer or GI bleed; or Failure or intolerance to at least three listed NSAIDS. Coverage limit: The maximum daily dose of celecoxib which will be reimbursed for the treatment of rheumatoid arthritis is 400mg. Coverage limit: LU Authorization Period: 1 year
Savings card: RxHelp ONE lists Celebrex (read 2026-09-10) — brand-name savings card, free; cannot be combined with another card on the same claim. (rxhelp.ca ↗)
1 brand, same coverage
Celebrex · DIN 02239941 Manufacturer: Upjohn Canada ULC; listing date 2000-04-17 Health Canada: Marketed since 2023-09-26 · brand CELEBREX · ATC M01AH01 CELECOXIB · form Capsule · route Oral · ingredients CELECOXIB 100 MG · company Bgp pharma ulc · schedule Prescription
Check this DIN again · Health Canada product record

Ministry pays: $0.1279 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=63442 · Verify on the e-Formulary ↗ (DIN 02239941)

Source record
DIN 02239941: Celebrex Raw flags: sec12=Y, sec3=Y Item: 280804075; group id 377; item number 0898; lccId 00064; manufacturer id UJC Source form: Cap; strength: 100mg Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below Source prices (unrounded): $0.8482; ministry $0.1279 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02239941 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=63442 Therapeutic Notes (formulary) NSAIDs have a high rate of serious adverse effects in the elderly. When prescribing NSAIDs, the minimal effective dose for the shortest period of time should be used. In nonspecific pain and/or osteoarthritis, in the absence of joint inflammation (swelling), acetaminophen is a better first choice for analgesia. The most effective treatment to prevent NSAID-gastritis is misoprostol; although H-2 antagonists, such as ranitidine or cimetidine, are commonly used, they are not as effective. NSAIDs can significantly aggravate hypertension and congestive heart failure; ASA in doses below 1 gram per day is a better choice than other NSAID options if anti-inflammatory effects are required in patients with these conditions. Low dose ASA has additional benefits for anti-platelet indications that are not provided by other NSAIDs, and should be given in preference or in addition to other NSAIDs for patients with vascular indications.
Interchangeable products
AG-Celecoxib · DIN 02437570 · $0.1279 Act Celecoxib · DIN 02420155 · $0.1279 Apo-Celecoxib · DIN 02418932 · $0.1279 Auro-Celecoxib · DIN 02445670 · $0.1279 Bio-Celecoxib · DIN 02426382 · $0.1279 Celecoxib · DIN 02429675 · $0.1279 Celecoxib · DIN 02436299 · $0.1279 Jamp-Celecoxib · DIN 02424533 · $0.1279 M-Celecoxib · DIN 02495465 · $0.1279 Mar-Celecoxib · DIN 02420058 · $0.1279 Mint-Celecoxib · DIN 02412497 · $0.1279 NRA-Celecoxib · DIN 02479737 · $0.1279 PMS-Celecoxib · DIN 02355442 · $0.1279 PMSC-Celecoxib · DIN 02517116 · $0.1279 Ran-Celecoxib · DIN 02412373 · $0.1279 Sdz Celecoxib · DIN 02442639 · $0.1279 Teva-Celecoxib · DIN 02288915 · $0.1279
Shortage status: resolved shortage (ended 2017-06-01); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02239941
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Celecoxib · DIN 02429675 · 100mg · capsule

Limited Use — Reason for Use code 316, 317 requiredMarketed · checked 2026-09-02
Write on scriptLU code 316, 317 (patient must meet the criteria below)
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Ontario Limited Use criteria — code 316, 317
Coverage limit: Osteoarthritis Reason for Use code 316 For patients who have failed an adequate trial of acetaminophen (e.g. acetaminophen 1g QID for several weeks) and have had: Coverage limit: History of a documented, clinically significant ulcer or GI bleed; or Failure or intolerance to at least three listed NSAIDS. Coverage limit: The maximum daily dose of celecoxib which will be reimbursed for the treatment of osteoarthritis is 200mg. Coverage limit: LU Authorization Period: 1 year Coverage limit: Rheumatoid arthritis Reason for Use code 317 For patients who have had: Coverage limit: History of a documented, clinically significant ulcer or GI bleed; or Failure or intolerance to at least three listed NSAIDS. Coverage limit: The maximum daily dose of celecoxib which will be reimbursed for the treatment of rheumatoid arthritis is 400mg. Coverage limit: LU Authorization Period: 1 year
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Celecoxib · DIN 02429675 Manufacturer: Sivem Pharmaceuticals ULC; listing date 2020-06-30 Health Canada: Marketed since 2018-07-04 · brand CELECOXIB · ATC M01AH01 CELECOXIB · form Capsule · route Oral · ingredients CELECOXIB 100 MG · company Sivem pharmaceuticals ulc · schedule Prescription
Check this DIN again · Health Canada product record

Celecoxib: Formulary list price $0.1279/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.1279 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=91412 · Verify on the e-Formulary ↗ (DIN 02429675)

Source record
DIN 02429675: Celecoxib Raw flags: sec12=Y, sec3=Y Item: 280804075; group id 377; item number 0898; lccId 00064; manufacturer id SIV Source form: Cap; strength: 100mg Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below Source prices (unrounded): $0.1279; ministry $0.1279 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02429675 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=91412 Therapeutic Notes (formulary) NSAIDs have a high rate of serious adverse effects in the elderly. When prescribing NSAIDs, the minimal effective dose for the shortest period of time should be used. In nonspecific pain and/or osteoarthritis, in the absence of joint inflammation (swelling), acetaminophen is a better first choice for analgesia. The most effective treatment to prevent NSAID-gastritis is misoprostol; although H-2 antagonists, such as ranitidine or cimetidine, are commonly used, they are not as effective. NSAIDs can significantly aggravate hypertension and congestive heart failure; ASA in doses below 1 gram per day is a better choice than other NSAID options if anti-inflammatory effects are required in patients with these conditions. Low dose ASA has additional benefits for anti-platelet indications that are not provided by other NSAIDs, and should be given in preference or in addition to other NSAIDs for patients with vascular indications.
Interchangeable products
AG-Celecoxib · DIN 02437570 · $0.1279 Act Celecoxib · DIN 02420155 · $0.1279 Apo-Celecoxib · DIN 02418932 · $0.1279 Auro-Celecoxib · DIN 02445670 · $0.1279 Bio-Celecoxib · DIN 02426382 · $0.1279 Celebrex · DIN 02239941 · $0.1279 Celecoxib · DIN 02436299 · $0.1279 Jamp-Celecoxib · DIN 02424533 · $0.1279 M-Celecoxib · DIN 02495465 · $0.1279 Mar-Celecoxib · DIN 02420058 · $0.1279 Mint-Celecoxib · DIN 02412497 · $0.1279 NRA-Celecoxib · DIN 02479737 · $0.1279 PMS-Celecoxib · DIN 02355442 · $0.1279 PMSC-Celecoxib · DIN 02517116 · $0.1279 Ran-Celecoxib · DIN 02412373 · $0.1279 Sdz Celecoxib · DIN 02442639 · $0.1279 Teva-Celecoxib · DIN 02288915 · $0.1279
Shortage status: resolved shortage (ended 2020-04-13); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02429675
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Celecoxib · DIN 02436299 · 100mg · capsule

Limited Use — Reason for Use code 316, 317 requiredMarketed · checked 2026-09-02
Write on scriptLU code 316, 317 (patient must meet the criteria below)
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Ontario Limited Use criteria — code 316, 317
Coverage limit: Osteoarthritis Reason for Use code 316 For patients who have failed an adequate trial of acetaminophen (e.g. acetaminophen 1g QID for several weeks) and have had: Coverage limit: History of a documented, clinically significant ulcer or GI bleed; or Failure or intolerance to at least three listed NSAIDS. Coverage limit: The maximum daily dose of celecoxib which will be reimbursed for the treatment of osteoarthritis is 200mg. Coverage limit: LU Authorization Period: 1 year Coverage limit: Rheumatoid arthritis Reason for Use code 317 For patients who have had: Coverage limit: History of a documented, clinically significant ulcer or GI bleed; or Failure or intolerance to at least three listed NSAIDS. Coverage limit: The maximum daily dose of celecoxib which will be reimbursed for the treatment of rheumatoid arthritis is 400mg. Coverage limit: LU Authorization Period: 1 year
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Celecoxib · DIN 02436299 Manufacturer: Sanis Health Inc.; listing date 2021-03-29 Health Canada: Marketed since 2021-02-02 · brand CELECOXIB · ATC M01AH01 CELECOXIB · form Capsule · route Oral · ingredients CELECOXIB 100 MG · company Sanis health inc · schedule Prescription
Check this DIN again · Health Canada product record

Celecoxib: Formulary list price $0.1279/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.1279 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=92062 · Verify on the e-Formulary ↗ (DIN 02436299)

Source record
DIN 02436299: Celecoxib Raw flags: sec12=Y, sec3=Y Item: 280804075; group id 377; item number 0898; lccId 00064; manufacturer id SAI Source form: Cap; strength: 100mg Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below Source prices (unrounded): $0.1279; ministry $0.1279 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02436299 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=92062 Therapeutic Notes (formulary) NSAIDs have a high rate of serious adverse effects in the elderly. When prescribing NSAIDs, the minimal effective dose for the shortest period of time should be used. In nonspecific pain and/or osteoarthritis, in the absence of joint inflammation (swelling), acetaminophen is a better first choice for analgesia. The most effective treatment to prevent NSAID-gastritis is misoprostol; although H-2 antagonists, such as ranitidine or cimetidine, are commonly used, they are not as effective. NSAIDs can significantly aggravate hypertension and congestive heart failure; ASA in doses below 1 gram per day is a better choice than other NSAID options if anti-inflammatory effects are required in patients with these conditions. Low dose ASA has additional benefits for anti-platelet indications that are not provided by other NSAIDs, and should be given in preference or in addition to other NSAIDs for patients with vascular indications.
Interchangeable products
AG-Celecoxib · DIN 02437570 · $0.1279 Act Celecoxib · DIN 02420155 · $0.1279 Apo-Celecoxib · DIN 02418932 · $0.1279 Auro-Celecoxib · DIN 02445670 · $0.1279 Bio-Celecoxib · DIN 02426382 · $0.1279 Celebrex · DIN 02239941 · $0.1279 Celecoxib · DIN 02429675 · $0.1279 Jamp-Celecoxib · DIN 02424533 · $0.1279 M-Celecoxib · DIN 02495465 · $0.1279 Mar-Celecoxib · DIN 02420058 · $0.1279 Mint-Celecoxib · DIN 02412497 · $0.1279 NRA-Celecoxib · DIN 02479737 · $0.1279 PMS-Celecoxib · DIN 02355442 · $0.1279 PMSC-Celecoxib · DIN 02517116 · $0.1279 Ran-Celecoxib · DIN 02412373 · $0.1279 Sdz Celecoxib · DIN 02442639 · $0.1279 Teva-Celecoxib · DIN 02288915 · $0.1279
Shortage status: avoided shortage; reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02436299
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Jamp-Celecoxib · DIN 02424533 · 100mg · capsule

Limited Use — Reason for Use code 316, 317 requiredMarketed · checked 2026-09-02
Write on scriptLU code 316, 317 (patient must meet the criteria below)
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Ontario Limited Use criteria — code 316, 317
Coverage limit: Osteoarthritis Reason for Use code 316 For patients who have failed an adequate trial of acetaminophen (e.g. acetaminophen 1g QID for several weeks) and have had: Coverage limit: History of a documented, clinically significant ulcer or GI bleed; or Failure or intolerance to at least three listed NSAIDS. Coverage limit: The maximum daily dose of celecoxib which will be reimbursed for the treatment of osteoarthritis is 200mg. Coverage limit: LU Authorization Period: 1 year Coverage limit: Rheumatoid arthritis Reason for Use code 317 For patients who have had: Coverage limit: History of a documented, clinically significant ulcer or GI bleed; or Failure or intolerance to at least three listed NSAIDS. Coverage limit: The maximum daily dose of celecoxib which will be reimbursed for the treatment of rheumatoid arthritis is 400mg. Coverage limit: LU Authorization Period: 1 year
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Jamp-Celecoxib · DIN 02424533 Manufacturer: Jamp Pharma Corporation; listing date 2015-01-28 Health Canada: Marketed since 2026-03-12 · brand JAMP CELECOXIB · ATC M01AH01 CELECOXIB · form Capsule · route Oral · ingredients CELECOXIB 100 MG · company Jamp pharma corporation · schedule Prescription
Check this DIN again · Health Canada product record

Jamp-Celecoxib: Formulary list price $0.1279/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.1279 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=90922 · Verify on the e-Formulary ↗ (DIN 02424533)

Source record
DIN 02424533: Jamp-Celecoxib Raw flags: sec12=Y, sec3=Y Item: 280804075; group id 377; item number 0898; lccId 00064; manufacturer id JPC Source form: Cap; strength: 100mg Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below Source prices (unrounded): $0.1279; ministry $0.1279 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02424533 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=90922 Therapeutic Notes (formulary) NSAIDs have a high rate of serious adverse effects in the elderly. When prescribing NSAIDs, the minimal effective dose for the shortest period of time should be used. In nonspecific pain and/or osteoarthritis, in the absence of joint inflammation (swelling), acetaminophen is a better first choice for analgesia. The most effective treatment to prevent NSAID-gastritis is misoprostol; although H-2 antagonists, such as ranitidine or cimetidine, are commonly used, they are not as effective. NSAIDs can significantly aggravate hypertension and congestive heart failure; ASA in doses below 1 gram per day is a better choice than other NSAID options if anti-inflammatory effects are required in patients with these conditions. Low dose ASA has additional benefits for anti-platelet indications that are not provided by other NSAIDs, and should be given in preference or in addition to other NSAIDs for patients with vascular indications.
Interchangeable products
AG-Celecoxib · DIN 02437570 · $0.1279 Act Celecoxib · DIN 02420155 · $0.1279 Apo-Celecoxib · DIN 02418932 · $0.1279 Auro-Celecoxib · DIN 02445670 · $0.1279 Bio-Celecoxib · DIN 02426382 · $0.1279 Celebrex · DIN 02239941 · $0.1279 Celecoxib · DIN 02429675 · $0.1279 Celecoxib · DIN 02436299 · $0.1279 M-Celecoxib · DIN 02495465 · $0.1279 Mar-Celecoxib · DIN 02420058 · $0.1279 Mint-Celecoxib · DIN 02412497 · $0.1279 NRA-Celecoxib · DIN 02479737 · $0.1279 PMS-Celecoxib · DIN 02355442 · $0.1279 PMSC-Celecoxib · DIN 02517116 · $0.1279 Ran-Celecoxib · DIN 02412373 · $0.1279 Sdz Celecoxib · DIN 02442639 · $0.1279 Teva-Celecoxib · DIN 02288915 · $0.1279
Shortage status: resolved shortage (ended 2023-09-26); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02424533
Shortage record checked 2026-09-13T08:10:21.292534+00:00

M-Celecoxib · DIN 02495465 · 100mg · capsule

Limited Use — Reason for Use code 316, 317 requiredMarketed · checked 2026-09-02
Write on scriptLU code 316, 317 (patient must meet the criteria below)
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Ontario Limited Use criteria — code 316, 317
Coverage limit: Osteoarthritis Reason for Use code 316 For patients who have failed an adequate trial of acetaminophen (e.g. acetaminophen 1g QID for several weeks) and have had: Coverage limit: History of a documented, clinically significant ulcer or GI bleed; or Failure or intolerance to at least three listed NSAIDS. Coverage limit: The maximum daily dose of celecoxib which will be reimbursed for the treatment of osteoarthritis is 200mg. Coverage limit: LU Authorization Period: 1 year Coverage limit: Rheumatoid arthritis Reason for Use code 317 For patients who have had: Coverage limit: History of a documented, clinically significant ulcer or GI bleed; or Failure or intolerance to at least three listed NSAIDS. Coverage limit: The maximum daily dose of celecoxib which will be reimbursed for the treatment of rheumatoid arthritis is 400mg. Coverage limit: LU Authorization Period: 1 year
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
M-Celecoxib · DIN 02495465 Manufacturer: Mantra Pharma Inc.; listing date 2021-10-29 Health Canada: Marketed since 2020-03-24 · brand M-CELECOXIB · ATC M01AH01 CELECOXIB · form Capsule · route Oral · ingredients CELECOXIB 100 MG · company Mantra pharma inc · schedule Prescription
Check this DIN again · Health Canada product record

M-Celecoxib: Formulary list price $0.1279/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.1279 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=98538 · Verify on the e-Formulary ↗ (DIN 02495465)

Source record
DIN 02495465: M-Celecoxib Raw flags: sec12=Y, sec3=Y Item: 280804075; group id 377; item number 0898; lccId 00064; manufacturer id MAT Source form: Cap; strength: 100mg Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below Source prices (unrounded): $0.1279; ministry $0.1279 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02495465 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=98538 Therapeutic Notes (formulary) NSAIDs have a high rate of serious adverse effects in the elderly. When prescribing NSAIDs, the minimal effective dose for the shortest period of time should be used. In nonspecific pain and/or osteoarthritis, in the absence of joint inflammation (swelling), acetaminophen is a better first choice for analgesia. The most effective treatment to prevent NSAID-gastritis is misoprostol; although H-2 antagonists, such as ranitidine or cimetidine, are commonly used, they are not as effective. NSAIDs can significantly aggravate hypertension and congestive heart failure; ASA in doses below 1 gram per day is a better choice than other NSAID options if anti-inflammatory effects are required in patients with these conditions. Low dose ASA has additional benefits for anti-platelet indications that are not provided by other NSAIDs, and should be given in preference or in addition to other NSAIDs for patients with vascular indications.
Interchangeable products
AG-Celecoxib · DIN 02437570 · $0.1279 Act Celecoxib · DIN 02420155 · $0.1279 Apo-Celecoxib · DIN 02418932 · $0.1279 Auro-Celecoxib · DIN 02445670 · $0.1279 Bio-Celecoxib · DIN 02426382 · $0.1279 Celebrex · DIN 02239941 · $0.1279 Celecoxib · DIN 02429675 · $0.1279 Celecoxib · DIN 02436299 · $0.1279 Jamp-Celecoxib · DIN 02424533 · $0.1279 Mar-Celecoxib · DIN 02420058 · $0.1279 Mint-Celecoxib · DIN 02412497 · $0.1279 NRA-Celecoxib · DIN 02479737 · $0.1279 PMS-Celecoxib · DIN 02355442 · $0.1279 PMSC-Celecoxib · DIN 02517116 · $0.1279 Ran-Celecoxib · DIN 02412373 · $0.1279 Sdz Celecoxib · DIN 02442639 · $0.1279 Teva-Celecoxib · DIN 02288915 · $0.1279
Shortage status: resolved shortage (ended 2026-06-22); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02495465
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Mar-Celecoxib · DIN 02420058 · 100mg · capsule

Limited Use — Reason for Use code 316, 317 requiredMarketed · checked 2026-09-02
Write on scriptLU code 316, 317 (patient must meet the criteria below)
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Ontario Limited Use criteria — code 316, 317
Coverage limit: Osteoarthritis Reason for Use code 316 For patients who have failed an adequate trial of acetaminophen (e.g. acetaminophen 1g QID for several weeks) and have had: Coverage limit: History of a documented, clinically significant ulcer or GI bleed; or Failure or intolerance to at least three listed NSAIDS. Coverage limit: The maximum daily dose of celecoxib which will be reimbursed for the treatment of osteoarthritis is 200mg. Coverage limit: LU Authorization Period: 1 year Coverage limit: Rheumatoid arthritis Reason for Use code 317 For patients who have had: Coverage limit: History of a documented, clinically significant ulcer or GI bleed; or Failure or intolerance to at least three listed NSAIDS. Coverage limit: The maximum daily dose of celecoxib which will be reimbursed for the treatment of rheumatoid arthritis is 400mg. Coverage limit: LU Authorization Period: 1 year
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Mar-Celecoxib · DIN 02420058 Manufacturer: Marcan Pharmaceuticals Inc.; listing date 2015-01-28 Health Canada: Marketed since 2014-11-17 · brand MAR-CELECOXIB · ATC M01AH01 CELECOXIB · form Capsule · route Oral · ingredients CELECOXIB 100 MG · company Marcan pharmaceuticals inc · schedule Prescription
Check this DIN again · Health Canada product record

Mar-Celecoxib: Formulary list price $0.1279/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.1279 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=90466 · Verify on the e-Formulary ↗ (DIN 02420058)

Source record
DIN 02420058: Mar-Celecoxib Raw flags: sec12=Y, sec3=Y Item: 280804075; group id 377; item number 0898; lccId 00064; manufacturer id MAR Source form: Cap; strength: 100mg Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below Source prices (unrounded): $0.1279; ministry $0.1279 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02420058 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=90466 Therapeutic Notes (formulary) NSAIDs have a high rate of serious adverse effects in the elderly. When prescribing NSAIDs, the minimal effective dose for the shortest period of time should be used. In nonspecific pain and/or osteoarthritis, in the absence of joint inflammation (swelling), acetaminophen is a better first choice for analgesia. The most effective treatment to prevent NSAID-gastritis is misoprostol; although H-2 antagonists, such as ranitidine or cimetidine, are commonly used, they are not as effective. NSAIDs can significantly aggravate hypertension and congestive heart failure; ASA in doses below 1 gram per day is a better choice than other NSAID options if anti-inflammatory effects are required in patients with these conditions. Low dose ASA has additional benefits for anti-platelet indications that are not provided by other NSAIDs, and should be given in preference or in addition to other NSAIDs for patients with vascular indications.
Interchangeable products
AG-Celecoxib · DIN 02437570 · $0.1279 Act Celecoxib · DIN 02420155 · $0.1279 Apo-Celecoxib · DIN 02418932 · $0.1279 Auro-Celecoxib · DIN 02445670 · $0.1279 Bio-Celecoxib · DIN 02426382 · $0.1279 Celebrex · DIN 02239941 · $0.1279 Celecoxib · DIN 02429675 · $0.1279 Celecoxib · DIN 02436299 · $0.1279 Jamp-Celecoxib · DIN 02424533 · $0.1279 M-Celecoxib · DIN 02495465 · $0.1279 Mint-Celecoxib · DIN 02412497 · $0.1279 NRA-Celecoxib · DIN 02479737 · $0.1279 PMS-Celecoxib · DIN 02355442 · $0.1279 PMSC-Celecoxib · DIN 02517116 · $0.1279 Ran-Celecoxib · DIN 02412373 · $0.1279 Sdz Celecoxib · DIN 02442639 · $0.1279 Teva-Celecoxib · DIN 02288915 · $0.1279
Shortage status: resolved shortage (ended 2018-09-13); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02420058
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Mint-Celecoxib · DIN 02412497 · 100mg · capsule

Limited Use — Reason for Use code 316, 317 requiredMarketed · checked 2026-09-02
Write on scriptLU code 316, 317 (patient must meet the criteria below)
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Ontario Limited Use criteria — code 316, 317
Coverage limit: Osteoarthritis Reason for Use code 316 For patients who have failed an adequate trial of acetaminophen (e.g. acetaminophen 1g QID for several weeks) and have had: Coverage limit: History of a documented, clinically significant ulcer or GI bleed; or Failure or intolerance to at least three listed NSAIDS. Coverage limit: The maximum daily dose of celecoxib which will be reimbursed for the treatment of osteoarthritis is 200mg. Coverage limit: LU Authorization Period: 1 year Coverage limit: Rheumatoid arthritis Reason for Use code 317 For patients who have had: Coverage limit: History of a documented, clinically significant ulcer or GI bleed; or Failure or intolerance to at least three listed NSAIDS. Coverage limit: The maximum daily dose of celecoxib which will be reimbursed for the treatment of rheumatoid arthritis is 400mg. Coverage limit: LU Authorization Period: 1 year
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Mint-Celecoxib · DIN 02412497 Manufacturer: Mint Pharmaceuticals Inc.; listing date 2015-01-28 Health Canada: Marketed since 2014-11-17 · brand MINT-CELECOXIB · ATC M01AH01 CELECOXIB · form Capsule · route Oral · ingredients CELECOXIB 100 MG · company Mint pharmaceuticals inc · schedule Prescription
Check this DIN again · Health Canada product record

Mint-Celecoxib: Formulary list price $0.1279/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.1279 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=89713 · Verify on the e-Formulary ↗ (DIN 02412497)

Source record
DIN 02412497: Mint-Celecoxib Raw flags: sec12=Y, sec3=Y Item: 280804075; group id 377; item number 0898; lccId 00064; manufacturer id MIN Source form: Cap; strength: 100mg Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below Source prices (unrounded): $0.1279; ministry $0.1279 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02412497 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=89713 Therapeutic Notes (formulary) NSAIDs have a high rate of serious adverse effects in the elderly. When prescribing NSAIDs, the minimal effective dose for the shortest period of time should be used. In nonspecific pain and/or osteoarthritis, in the absence of joint inflammation (swelling), acetaminophen is a better first choice for analgesia. The most effective treatment to prevent NSAID-gastritis is misoprostol; although H-2 antagonists, such as ranitidine or cimetidine, are commonly used, they are not as effective. NSAIDs can significantly aggravate hypertension and congestive heart failure; ASA in doses below 1 gram per day is a better choice than other NSAID options if anti-inflammatory effects are required in patients with these conditions. Low dose ASA has additional benefits for anti-platelet indications that are not provided by other NSAIDs, and should be given in preference or in addition to other NSAIDs for patients with vascular indications.
Interchangeable products
AG-Celecoxib · DIN 02437570 · $0.1279 Act Celecoxib · DIN 02420155 · $0.1279 Apo-Celecoxib · DIN 02418932 · $0.1279 Auro-Celecoxib · DIN 02445670 · $0.1279 Bio-Celecoxib · DIN 02426382 · $0.1279 Celebrex · DIN 02239941 · $0.1279 Celecoxib · DIN 02429675 · $0.1279 Celecoxib · DIN 02436299 · $0.1279 Jamp-Celecoxib · DIN 02424533 · $0.1279 M-Celecoxib · DIN 02495465 · $0.1279 Mar-Celecoxib · DIN 02420058 · $0.1279 NRA-Celecoxib · DIN 02479737 · $0.1279 PMS-Celecoxib · DIN 02355442 · $0.1279 PMSC-Celecoxib · DIN 02517116 · $0.1279 Ran-Celecoxib · DIN 02412373 · $0.1279 Sdz Celecoxib · DIN 02442639 · $0.1279 Teva-Celecoxib · DIN 02288915 · $0.1279
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02412497
Shortage record checked 2026-09-13T08:10:21.292534+00:00

NRA-Celecoxib · DIN 02479737 · 100mg · capsule

Limited Use — Reason for Use code 316, 317 requiredMarketed · checked 2026-09-02
Write on scriptLU code 316, 317 (patient must meet the criteria below)
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Ontario Limited Use criteria — code 316, 317
Coverage limit: Osteoarthritis Reason for Use code 316 For patients who have failed an adequate trial of acetaminophen (e.g. acetaminophen 1g QID for several weeks) and have had: Coverage limit: History of a documented, clinically significant ulcer or GI bleed; or Failure or intolerance to at least three listed NSAIDS. Coverage limit: The maximum daily dose of celecoxib which will be reimbursed for the treatment of osteoarthritis is 200mg. Coverage limit: LU Authorization Period: 1 year Coverage limit: Rheumatoid arthritis Reason for Use code 317 For patients who have had: Coverage limit: History of a documented, clinically significant ulcer or GI bleed; or Failure or intolerance to at least three listed NSAIDS. Coverage limit: The maximum daily dose of celecoxib which will be reimbursed for the treatment of rheumatoid arthritis is 400mg. Coverage limit: LU Authorization Period: 1 year
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
NRA-Celecoxib · DIN 02479737 Manufacturer: Nora Pharma; listing date 2020-06-30 Health Canada: Marketed since 2019-07-02 · brand NRA-CELECOXIB · ATC M01AH01 CELECOXIB · form Capsule · route Oral · ingredients CELECOXIB 100 MG · company Nora pharma inc · schedule Prescription
Check this DIN again · Health Canada product record

NRA-Celecoxib: Formulary list price $0.1279/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.1279 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=97003 · Verify on the e-Formulary ↗ (DIN 02479737)

Source record
DIN 02479737: NRA-Celecoxib Raw flags: sec12=Y, sec3=Y Item: 280804075; group id 377; item number 0898; lccId 00064; manufacturer id NRA Source form: Cap; strength: 100mg Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below Source prices (unrounded): $0.1279; ministry $0.1279 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02479737 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=97003 Therapeutic Notes (formulary) NSAIDs have a high rate of serious adverse effects in the elderly. When prescribing NSAIDs, the minimal effective dose for the shortest period of time should be used. In nonspecific pain and/or osteoarthritis, in the absence of joint inflammation (swelling), acetaminophen is a better first choice for analgesia. The most effective treatment to prevent NSAID-gastritis is misoprostol; although H-2 antagonists, such as ranitidine or cimetidine, are commonly used, they are not as effective. NSAIDs can significantly aggravate hypertension and congestive heart failure; ASA in doses below 1 gram per day is a better choice than other NSAID options if anti-inflammatory effects are required in patients with these conditions. Low dose ASA has additional benefits for anti-platelet indications that are not provided by other NSAIDs, and should be given in preference or in addition to other NSAIDs for patients with vascular indications.
Interchangeable products
AG-Celecoxib · DIN 02437570 · $0.1279 Act Celecoxib · DIN 02420155 · $0.1279 Apo-Celecoxib · DIN 02418932 · $0.1279 Auro-Celecoxib · DIN 02445670 · $0.1279 Bio-Celecoxib · DIN 02426382 · $0.1279 Celebrex · DIN 02239941 · $0.1279 Celecoxib · DIN 02429675 · $0.1279 Celecoxib · DIN 02436299 · $0.1279 Jamp-Celecoxib · DIN 02424533 · $0.1279 M-Celecoxib · DIN 02495465 · $0.1279 Mar-Celecoxib · DIN 02420058 · $0.1279 Mint-Celecoxib · DIN 02412497 · $0.1279 PMS-Celecoxib · DIN 02355442 · $0.1279 PMSC-Celecoxib · DIN 02517116 · $0.1279 Ran-Celecoxib · DIN 02412373 · $0.1279 Sdz Celecoxib · DIN 02442639 · $0.1279 Teva-Celecoxib · DIN 02288915 · $0.1279
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02479737
Shortage record checked 2026-09-13T08:10:21.292534+00:00

PMSC-Celecoxib · DIN 02517116 · 100mg · capsule

Limited Use — Reason for Use code 316, 317 requiredMarketed · checked 2026-09-02
Write on scriptLU code 316, 317 (patient must meet the criteria below)
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Ontario Limited Use criteria — code 316, 317
Coverage limit: Osteoarthritis Reason for Use code 316 For patients who have failed an adequate trial of acetaminophen (e.g. acetaminophen 1g QID for several weeks) and have had: Coverage limit: History of a documented, clinically significant ulcer or GI bleed; or Failure or intolerance to at least three listed NSAIDS. Coverage limit: The maximum daily dose of celecoxib which will be reimbursed for the treatment of osteoarthritis is 200mg. Coverage limit: LU Authorization Period: 1 year Coverage limit: Rheumatoid arthritis Reason for Use code 317 For patients who have had: Coverage limit: History of a documented, clinically significant ulcer or GI bleed; or Failure or intolerance to at least three listed NSAIDS. Coverage limit: The maximum daily dose of celecoxib which will be reimbursed for the treatment of rheumatoid arthritis is 400mg. Coverage limit: LU Authorization Period: 1 year
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
PMSC-Celecoxib · DIN 02517116 Manufacturer: Pharmascience Inc.; listing date 2022-01-31 Health Canada: Marketed since 2021-11-09 · brand PMSC-CELECOXIB · ATC M01AH01 CELECOXIB · form Capsule · route Oral · ingredients CELECOXIB 100 MG · company Pharmascience inc · schedule Prescription
Check this DIN again · Health Canada product record

PMSC-Celecoxib: Formulary list price $0.1279/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.1279 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=100645 · Verify on the e-Formulary ↗ (DIN 02517116)

Source record
DIN 02517116: PMSC-Celecoxib Raw flags: sec12=Y, sec3=Y Item: 280804075; group id 377; item number 0898; lccId 00064; manufacturer id PMS Source form: Cap; strength: 100mg Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below Source prices (unrounded): $0.1279; ministry $0.1279 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02517116 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=100645 Therapeutic Notes (formulary) NSAIDs have a high rate of serious adverse effects in the elderly. When prescribing NSAIDs, the minimal effective dose for the shortest period of time should be used. In nonspecific pain and/or osteoarthritis, in the absence of joint inflammation (swelling), acetaminophen is a better first choice for analgesia. The most effective treatment to prevent NSAID-gastritis is misoprostol; although H-2 antagonists, such as ranitidine or cimetidine, are commonly used, they are not as effective. NSAIDs can significantly aggravate hypertension and congestive heart failure; ASA in doses below 1 gram per day is a better choice than other NSAID options if anti-inflammatory effects are required in patients with these conditions. Low dose ASA has additional benefits for anti-platelet indications that are not provided by other NSAIDs, and should be given in preference or in addition to other NSAIDs for patients with vascular indications.
Interchangeable products
AG-Celecoxib · DIN 02437570 · $0.1279 Act Celecoxib · DIN 02420155 · $0.1279 Apo-Celecoxib · DIN 02418932 · $0.1279 Auro-Celecoxib · DIN 02445670 · $0.1279 Bio-Celecoxib · DIN 02426382 · $0.1279 Celebrex · DIN 02239941 · $0.1279 Celecoxib · DIN 02429675 · $0.1279 Celecoxib · DIN 02436299 · $0.1279 Jamp-Celecoxib · DIN 02424533 · $0.1279 M-Celecoxib · DIN 02495465 · $0.1279 Mar-Celecoxib · DIN 02420058 · $0.1279 Mint-Celecoxib · DIN 02412497 · $0.1279 NRA-Celecoxib · DIN 02479737 · $0.1279 PMS-Celecoxib · DIN 02355442 · $0.1279 Ran-Celecoxib · DIN 02412373 · $0.1279 Sdz Celecoxib · DIN 02442639 · $0.1279 Teva-Celecoxib · DIN 02288915 · $0.1279
Shortage status: resolved shortage (ended 2025-05-20); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02517116
Shortage record checked 2026-09-13T08:10:21.292534+00:00

AG-Celecoxib · DIN 02437589 · 200mg · capsule

Limited Use — Reason for Use code 316, 317 requiredMarketed · checked 2026-09-02
Write on scriptLU code 316, 317 (patient must meet the criteria below)
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Ontario Limited Use criteria — code 316, 317
Coverage limit: Osteoarthritis Reason for Use code 316 For patients who have failed an adequate trial of acetaminophen (e.g. acetaminophen 1g QID for several weeks) and have had: Coverage limit: History of a documented, clinically significant ulcer or GI bleed; or Failure or intolerance to at least three listed NSAIDS. Coverage limit: The maximum daily dose of celecoxib which will be reimbursed for the treatment of osteoarthritis is 200mg. Coverage limit: LU Authorization Period: 1 year Coverage limit: Rheumatoid arthritis Reason for Use code 317 For patients who have had: Coverage limit: History of a documented, clinically significant ulcer or GI bleed; or Failure or intolerance to at least three listed NSAIDS. Coverage limit: The maximum daily dose of celecoxib which will be reimbursed for the treatment of rheumatoid arthritis is 400mg. Coverage limit: LU Authorization Period: 1 year
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
AG-Celecoxib · DIN 02437589 Manufacturer: Angita Pharma Inc.; listing date 2020-11-30 Health Canada: Marketed since 2019-05-13 · brand AG-CELECOXIB · ATC M01AH01 CELECOXIB · form Capsule · route Oral · ingredients CELECOXIB 200 MG · company Angita pharma inc. · schedule Prescription
Check this DIN again · Health Canada product record

AG-Celecoxib: Formulary list price $0.2558/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.2558 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=92191 · Verify on the e-Formulary ↗ (DIN 02437589)

Source record
DIN 02437589: AG-Celecoxib Raw flags: sec12=Y, sec3=Y Item: 280804076; group id 377; item number 0899; lccId 00064; manufacturer id ANG Source form: Cap; strength: 200mg Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below Source prices (unrounded): $0.2558; ministry $0.2558 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02437589 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=92191 Therapeutic Notes (formulary) NSAIDs have a high rate of serious adverse effects in the elderly. When prescribing NSAIDs, the minimal effective dose for the shortest period of time should be used. In nonspecific pain and/or osteoarthritis, in the absence of joint inflammation (swelling), acetaminophen is a better first choice for analgesia. The most effective treatment to prevent NSAID-gastritis is misoprostol; although H-2 antagonists, such as ranitidine or cimetidine, are commonly used, they are not as effective. NSAIDs can significantly aggravate hypertension and congestive heart failure; ASA in doses below 1 gram per day is a better choice than other NSAID options if anti-inflammatory effects are required in patients with these conditions. Low dose ASA has additional benefits for anti-platelet indications that are not provided by other NSAIDs, and should be given in preference or in addition to other NSAIDs for patients with vascular indications.
Interchangeable products
Act Celecoxib · DIN 02420163 · $0.2558 Apo-Celecoxib · DIN 02418940 · $0.2558 Auro-Celecoxib · DIN 02445689 · $0.2558 Bio-Celecoxib · DIN 02426390 · $0.2558 Celebrex · DIN 02239942 · $0.2558 Celecoxib · DIN 02429683 · $0.2558 Celecoxib · DIN 02436302 · $0.2558 Jamp-Celecoxib · DIN 02424541 · $0.2558 M-Celecoxib · DIN 02495473 · $0.2558 Mar-Celecoxib · DIN 02420066 · $0.2558 Mint-Celecoxib · DIN 02412500 · $0.2558 NRA-Celecoxib · DIN 02479745 · $0.2558 PMS-Celecoxib · DIN 02355450 · $0.2558 PMSC-Celecoxib · DIN 02517124 · $0.2558 Ran-Celecoxib · DIN 02412381 · $0.2558 Sdz Celecoxib · DIN 02442647 · $0.2558 Teva-Celecoxib · DIN 02288923 · $0.2558
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02437589
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Apo-Celecoxib · DIN 02418940 · 200mg · capsule

Limited Use — Reason for Use code 316, 317 requiredMarketed · checked 2026-09-02
Write on scriptLU code 316, 317 (patient must meet the criteria below)
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Ontario Limited Use criteria — code 316, 317
Coverage limit: Osteoarthritis Reason for Use code 316 For patients who have failed an adequate trial of acetaminophen (e.g. acetaminophen 1g QID for several weeks) and have had: Coverage limit: History of a documented, clinically significant ulcer or GI bleed; or Failure or intolerance to at least three listed NSAIDS. Coverage limit: The maximum daily dose of celecoxib which will be reimbursed for the treatment of osteoarthritis is 200mg. Coverage limit: LU Authorization Period: 1 year Coverage limit: Rheumatoid arthritis Reason for Use code 317 For patients who have had: Coverage limit: History of a documented, clinically significant ulcer or GI bleed; or Failure or intolerance to at least three listed NSAIDS. Coverage limit: The maximum daily dose of celecoxib which will be reimbursed for the treatment of rheumatoid arthritis is 400mg. Coverage limit: LU Authorization Period: 1 year
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Apo-Celecoxib · DIN 02418940 Manufacturer: Apotex Inc.; listing date 2015-01-28 Health Canada: Marketed since 2014-11-17 · brand APO-CELECOXIB · ATC M01AH01 CELECOXIB · form Capsule · route Oral · ingredients CELECOXIB 200 MG · company Apotex inc · schedule Prescription
Check this DIN again · Health Canada product record

Apo-Celecoxib: Formulary list price $0.2558/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.2558 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=90348 · Verify on the e-Formulary ↗ (DIN 02418940)

Source record
DIN 02418940: Apo-Celecoxib Raw flags: sec12=Y, sec3=Y Item: 280804076; group id 377; item number 0899; lccId 00064; manufacturer id APX Source form: Cap; strength: 200mg Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below Source prices (unrounded): $0.2558; ministry $0.2558 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02418940 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=90348 Therapeutic Notes (formulary) NSAIDs have a high rate of serious adverse effects in the elderly. When prescribing NSAIDs, the minimal effective dose for the shortest period of time should be used. In nonspecific pain and/or osteoarthritis, in the absence of joint inflammation (swelling), acetaminophen is a better first choice for analgesia. The most effective treatment to prevent NSAID-gastritis is misoprostol; although H-2 antagonists, such as ranitidine or cimetidine, are commonly used, they are not as effective. NSAIDs can significantly aggravate hypertension and congestive heart failure; ASA in doses below 1 gram per day is a better choice than other NSAID options if anti-inflammatory effects are required in patients with these conditions. Low dose ASA has additional benefits for anti-platelet indications that are not provided by other NSAIDs, and should be given in preference or in addition to other NSAIDs for patients with vascular indications.
Interchangeable products
AG-Celecoxib · DIN 02437589 · $0.2558 Act Celecoxib · DIN 02420163 · $0.2558 Auro-Celecoxib · DIN 02445689 · $0.2558 Bio-Celecoxib · DIN 02426390 · $0.2558 Celebrex · DIN 02239942 · $0.2558 Celecoxib · DIN 02429683 · $0.2558 Celecoxib · DIN 02436302 · $0.2558 Jamp-Celecoxib · DIN 02424541 · $0.2558 M-Celecoxib · DIN 02495473 · $0.2558 Mar-Celecoxib · DIN 02420066 · $0.2558 Mint-Celecoxib · DIN 02412500 · $0.2558 NRA-Celecoxib · DIN 02479745 · $0.2558 PMS-Celecoxib · DIN 02355450 · $0.2558 PMSC-Celecoxib · DIN 02517124 · $0.2558 Ran-Celecoxib · DIN 02412381 · $0.2558 Sdz Celecoxib · DIN 02442647 · $0.2558 Teva-Celecoxib · DIN 02288923 · $0.2558
Shortage status: resolved shortage (ended 2024-12-12); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02418940
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Auro-Celecoxib · DIN 02445689 · 200mg · capsule

Limited Use — Reason for Use code 316, 317 requiredMarketed · checked 2026-09-02
Write on scriptLU code 316, 317 (patient must meet the criteria below)
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Ontario Limited Use criteria — code 316, 317
Coverage limit: Osteoarthritis Reason for Use code 316 For patients who have failed an adequate trial of acetaminophen (e.g. acetaminophen 1g QID for several weeks) and have had: Coverage limit: History of a documented, clinically significant ulcer or GI bleed; or Failure or intolerance to at least three listed NSAIDS. Coverage limit: The maximum daily dose of celecoxib which will be reimbursed for the treatment of osteoarthritis is 200mg. Coverage limit: LU Authorization Period: 1 year Coverage limit: Rheumatoid arthritis Reason for Use code 317 For patients who have had: Coverage limit: History of a documented, clinically significant ulcer or GI bleed; or Failure or intolerance to at least three listed NSAIDS. Coverage limit: The maximum daily dose of celecoxib which will be reimbursed for the treatment of rheumatoid arthritis is 400mg. Coverage limit: LU Authorization Period: 1 year
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Auro-Celecoxib · DIN 02445689 Manufacturer: Auro Pharma Inc.; listing date 2016-07-28 Health Canada: Marketed since 2015-12-02 · brand AURO-CELECOXIB · ATC M01AH01 CELECOXIB · form Capsule · route Oral · ingredients CELECOXIB 200 MG · company Auro pharma inc · schedule Prescription
Check this DIN again · Health Canada product record

Auro-Celecoxib: Formulary list price $0.2558/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.2558 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=93096 · Verify on the e-Formulary ↗ (DIN 02445689)

Source record
DIN 02445689: Auro-Celecoxib Raw flags: sec12=Y, sec3=Y Item: 280804076; group id 377; item number 0899; lccId 00064; manufacturer id AUR Source form: Cap; strength: 200mg Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below Source prices (unrounded): $0.2558; ministry $0.2558 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02445689 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=93096 Therapeutic Notes (formulary) NSAIDs have a high rate of serious adverse effects in the elderly. When prescribing NSAIDs, the minimal effective dose for the shortest period of time should be used. In nonspecific pain and/or osteoarthritis, in the absence of joint inflammation (swelling), acetaminophen is a better first choice for analgesia. The most effective treatment to prevent NSAID-gastritis is misoprostol; although H-2 antagonists, such as ranitidine or cimetidine, are commonly used, they are not as effective. NSAIDs can significantly aggravate hypertension and congestive heart failure; ASA in doses below 1 gram per day is a better choice than other NSAID options if anti-inflammatory effects are required in patients with these conditions. Low dose ASA has additional benefits for anti-platelet indications that are not provided by other NSAIDs, and should be given in preference or in addition to other NSAIDs for patients with vascular indications.
Interchangeable products
AG-Celecoxib · DIN 02437589 · $0.2558 Act Celecoxib · DIN 02420163 · $0.2558 Apo-Celecoxib · DIN 02418940 · $0.2558 Bio-Celecoxib · DIN 02426390 · $0.2558 Celebrex · DIN 02239942 · $0.2558 Celecoxib · DIN 02429683 · $0.2558 Celecoxib · DIN 02436302 · $0.2558 Jamp-Celecoxib · DIN 02424541 · $0.2558 M-Celecoxib · DIN 02495473 · $0.2558 Mar-Celecoxib · DIN 02420066 · $0.2558 Mint-Celecoxib · DIN 02412500 · $0.2558 NRA-Celecoxib · DIN 02479745 · $0.2558 PMS-Celecoxib · DIN 02355450 · $0.2558 PMSC-Celecoxib · DIN 02517124 · $0.2558 Ran-Celecoxib · DIN 02412381 · $0.2558 Sdz Celecoxib · DIN 02442647 · $0.2558 Teva-Celecoxib · DIN 02288923 · $0.2558
Shortage status: resolved shortage (ended 2024-06-28); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02445689
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Bio-Celecoxib · DIN 02426390 · 200mg · capsule

Limited Use — Reason for Use code 316, 317 requiredMarketed · checked 2026-09-02
Write on scriptLU code 316, 317 (patient must meet the criteria below)
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Ontario Limited Use criteria — code 316, 317
Coverage limit: Osteoarthritis Reason for Use code 316 For patients who have failed an adequate trial of acetaminophen (e.g. acetaminophen 1g QID for several weeks) and have had: Coverage limit: History of a documented, clinically significant ulcer or GI bleed; or Failure or intolerance to at least three listed NSAIDS. Coverage limit: The maximum daily dose of celecoxib which will be reimbursed for the treatment of osteoarthritis is 200mg. Coverage limit: LU Authorization Period: 1 year Coverage limit: Rheumatoid arthritis Reason for Use code 317 For patients who have had: Coverage limit: History of a documented, clinically significant ulcer or GI bleed; or Failure or intolerance to at least three listed NSAIDS. Coverage limit: The maximum daily dose of celecoxib which will be reimbursed for the treatment of rheumatoid arthritis is 400mg. Coverage limit: LU Authorization Period: 1 year
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Bio-Celecoxib · DIN 02426390 Manufacturer: Biomed Pharma; listing date 2016-02-25 Health Canada: Marketed since 2014-12-05 · brand BIO-CELECOXIB · ATC M01AH01 CELECOXIB · form Capsule · route Oral · ingredients CELECOXIB 200 MG · company Biomed pharma · schedule Prescription
Check this DIN again · Health Canada product record

Bio-Celecoxib: Formulary list price $0.2558/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.2558 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=91098 · Verify on the e-Formulary ↗ (DIN 02426390)

Source record
DIN 02426390: Bio-Celecoxib Raw flags: sec12=Y, sec3=Y Item: 280804076; group id 377; item number 0899; lccId 00064; manufacturer id BMP Source form: Cap; strength: 200mg Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below Source prices (unrounded): $0.2558; ministry $0.2558 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02426390 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=91098 Therapeutic Notes (formulary) NSAIDs have a high rate of serious adverse effects in the elderly. When prescribing NSAIDs, the minimal effective dose for the shortest period of time should be used. In nonspecific pain and/or osteoarthritis, in the absence of joint inflammation (swelling), acetaminophen is a better first choice for analgesia. The most effective treatment to prevent NSAID-gastritis is misoprostol; although H-2 antagonists, such as ranitidine or cimetidine, are commonly used, they are not as effective. NSAIDs can significantly aggravate hypertension and congestive heart failure; ASA in doses below 1 gram per day is a better choice than other NSAID options if anti-inflammatory effects are required in patients with these conditions. Low dose ASA has additional benefits for anti-platelet indications that are not provided by other NSAIDs, and should be given in preference or in addition to other NSAIDs for patients with vascular indications.
Interchangeable products
AG-Celecoxib · DIN 02437589 · $0.2558 Act Celecoxib · DIN 02420163 · $0.2558 Apo-Celecoxib · DIN 02418940 · $0.2558 Auro-Celecoxib · DIN 02445689 · $0.2558 Celebrex · DIN 02239942 · $0.2558 Celecoxib · DIN 02429683 · $0.2558 Celecoxib · DIN 02436302 · $0.2558 Jamp-Celecoxib · DIN 02424541 · $0.2558 M-Celecoxib · DIN 02495473 · $0.2558 Mar-Celecoxib · DIN 02420066 · $0.2558 Mint-Celecoxib · DIN 02412500 · $0.2558 NRA-Celecoxib · DIN 02479745 · $0.2558 PMS-Celecoxib · DIN 02355450 · $0.2558 PMSC-Celecoxib · DIN 02517124 · $0.2558 Ran-Celecoxib · DIN 02412381 · $0.2558 Sdz Celecoxib · DIN 02442647 · $0.2558 Teva-Celecoxib · DIN 02288923 · $0.2558
Shortage status: resolved shortage (ended 2019-07-20); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02426390
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Celebrex · DIN 02239942 · 200mg · capsule

Limited Use — Reason for Use code 316, 317 requiredMarketed · checked 2026-09-02
Write on scriptLU code 316, 317 (patient must meet the criteria below)
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Ontario Limited Use criteria — code 316, 317
Coverage limit: Osteoarthritis Reason for Use code 316 For patients who have failed an adequate trial of acetaminophen (e.g. acetaminophen 1g QID for several weeks) and have had: Coverage limit: History of a documented, clinically significant ulcer or GI bleed; or Failure or intolerance to at least three listed NSAIDS. Coverage limit: The maximum daily dose of celecoxib which will be reimbursed for the treatment of osteoarthritis is 200mg. Coverage limit: LU Authorization Period: 1 year Coverage limit: Rheumatoid arthritis Reason for Use code 317 For patients who have had: Coverage limit: History of a documented, clinically significant ulcer or GI bleed; or Failure or intolerance to at least three listed NSAIDS. Coverage limit: The maximum daily dose of celecoxib which will be reimbursed for the treatment of rheumatoid arthritis is 400mg. Coverage limit: LU Authorization Period: 1 year
Savings card: RxHelp ONE lists Celebrex (read 2026-09-10) — brand-name savings card, free; cannot be combined with another card on the same claim. (rxhelp.ca ↗)
1 brand, same coverage
Celebrex · DIN 02239942 Manufacturer: Upjohn Canada ULC; listing date 2000-04-17 Health Canada: Marketed since 2023-09-26 · brand CELEBREX · ATC M01AH01 CELECOXIB · form Capsule · route Oral · ingredients CELECOXIB 200 MG · company Bgp pharma ulc · schedule Prescription
Check this DIN again · Health Canada product record

Ministry pays: $0.2558 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=63443 · Verify on the e-Formulary ↗ (DIN 02239942)

Source record
DIN 02239942: Celebrex Raw flags: sec12=Y, sec3=Y Item: 280804076; group id 377; item number 0899; lccId 00064; manufacturer id UJC Source form: Cap; strength: 200mg Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below Source prices (unrounded): $1.6966; ministry $0.2558 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02239942 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=63443 Therapeutic Notes (formulary) NSAIDs have a high rate of serious adverse effects in the elderly. When prescribing NSAIDs, the minimal effective dose for the shortest period of time should be used. In nonspecific pain and/or osteoarthritis, in the absence of joint inflammation (swelling), acetaminophen is a better first choice for analgesia. The most effective treatment to prevent NSAID-gastritis is misoprostol; although H-2 antagonists, such as ranitidine or cimetidine, are commonly used, they are not as effective. NSAIDs can significantly aggravate hypertension and congestive heart failure; ASA in doses below 1 gram per day is a better choice than other NSAID options if anti-inflammatory effects are required in patients with these conditions. Low dose ASA has additional benefits for anti-platelet indications that are not provided by other NSAIDs, and should be given in preference or in addition to other NSAIDs for patients with vascular indications.
Interchangeable products
AG-Celecoxib · DIN 02437589 · $0.2558 Act Celecoxib · DIN 02420163 · $0.2558 Apo-Celecoxib · DIN 02418940 · $0.2558 Auro-Celecoxib · DIN 02445689 · $0.2558 Bio-Celecoxib · DIN 02426390 · $0.2558 Celecoxib · DIN 02429683 · $0.2558 Celecoxib · DIN 02436302 · $0.2558 Jamp-Celecoxib · DIN 02424541 · $0.2558 M-Celecoxib · DIN 02495473 · $0.2558 Mar-Celecoxib · DIN 02420066 · $0.2558 Mint-Celecoxib · DIN 02412500 · $0.2558 NRA-Celecoxib · DIN 02479745 · $0.2558 PMS-Celecoxib · DIN 02355450 · $0.2558 PMSC-Celecoxib · DIN 02517124 · $0.2558 Ran-Celecoxib · DIN 02412381 · $0.2558 Sdz Celecoxib · DIN 02442647 · $0.2558 Teva-Celecoxib · DIN 02288923 · $0.2558
Shortage status: resolved shortage (ended 2022-06-03); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02239942
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Celecoxib · DIN 02429683 · 200mg · capsule

Limited Use — Reason for Use code 316, 317 requiredMarketed · checked 2026-09-02
Write on scriptLU code 316, 317 (patient must meet the criteria below)
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Ontario Limited Use criteria — code 316, 317
Coverage limit: Osteoarthritis Reason for Use code 316 For patients who have failed an adequate trial of acetaminophen (e.g. acetaminophen 1g QID for several weeks) and have had: Coverage limit: History of a documented, clinically significant ulcer or GI bleed; or Failure or intolerance to at least three listed NSAIDS. Coverage limit: The maximum daily dose of celecoxib which will be reimbursed for the treatment of osteoarthritis is 200mg. Coverage limit: LU Authorization Period: 1 year Coverage limit: Rheumatoid arthritis Reason for Use code 317 For patients who have had: Coverage limit: History of a documented, clinically significant ulcer or GI bleed; or Failure or intolerance to at least three listed NSAIDS. Coverage limit: The maximum daily dose of celecoxib which will be reimbursed for the treatment of rheumatoid arthritis is 400mg. Coverage limit: LU Authorization Period: 1 year
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Celecoxib · DIN 02429683 Manufacturer: Sivem Pharmaceuticals ULC; listing date 2020-06-30 Health Canada: Marketed since 2018-07-04 · brand CELECOXIB · ATC M01AH01 CELECOXIB · form Capsule · route Oral · ingredients CELECOXIB 200 MG · company Sivem pharmaceuticals ulc · schedule Prescription
Check this DIN again · Health Canada product record

Celecoxib: Formulary list price $0.2558/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.2558 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=91413 · Verify on the e-Formulary ↗ (DIN 02429683)

Source record
DIN 02429683: Celecoxib Raw flags: sec12=Y, sec3=Y Item: 280804076; group id 377; item number 0899; lccId 00064; manufacturer id SIV Source form: Cap; strength: 200mg Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below Source prices (unrounded): $0.2558; ministry $0.2558 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02429683 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=91413 Therapeutic Notes (formulary) NSAIDs have a high rate of serious adverse effects in the elderly. When prescribing NSAIDs, the minimal effective dose for the shortest period of time should be used. In nonspecific pain and/or osteoarthritis, in the absence of joint inflammation (swelling), acetaminophen is a better first choice for analgesia. The most effective treatment to prevent NSAID-gastritis is misoprostol; although H-2 antagonists, such as ranitidine or cimetidine, are commonly used, they are not as effective. NSAIDs can significantly aggravate hypertension and congestive heart failure; ASA in doses below 1 gram per day is a better choice than other NSAID options if anti-inflammatory effects are required in patients with these conditions. Low dose ASA has additional benefits for anti-platelet indications that are not provided by other NSAIDs, and should be given in preference or in addition to other NSAIDs for patients with vascular indications.
Interchangeable products
AG-Celecoxib · DIN 02437589 · $0.2558 Act Celecoxib · DIN 02420163 · $0.2558 Apo-Celecoxib · DIN 02418940 · $0.2558 Auro-Celecoxib · DIN 02445689 · $0.2558 Bio-Celecoxib · DIN 02426390 · $0.2558 Celebrex · DIN 02239942 · $0.2558 Celecoxib · DIN 02436302 · $0.2558 Jamp-Celecoxib · DIN 02424541 · $0.2558 M-Celecoxib · DIN 02495473 · $0.2558 Mar-Celecoxib · DIN 02420066 · $0.2558 Mint-Celecoxib · DIN 02412500 · $0.2558 NRA-Celecoxib · DIN 02479745 · $0.2558 PMS-Celecoxib · DIN 02355450 · $0.2558 PMSC-Celecoxib · DIN 02517124 · $0.2558 Ran-Celecoxib · DIN 02412381 · $0.2558 Sdz Celecoxib · DIN 02442647 · $0.2558 Teva-Celecoxib · DIN 02288923 · $0.2558
Shortage status: resolved shortage (ended 2020-08-10); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02429683
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Celecoxib · DIN 02436302 · 200mg · capsule

Limited Use — Reason for Use code 316, 317 requiredMarketed · checked 2026-09-02
Write on scriptLU code 316, 317 (patient must meet the criteria below)
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Ontario Limited Use criteria — code 316, 317
Coverage limit: Osteoarthritis Reason for Use code 316 For patients who have failed an adequate trial of acetaminophen (e.g. acetaminophen 1g QID for several weeks) and have had: Coverage limit: History of a documented, clinically significant ulcer or GI bleed; or Failure or intolerance to at least three listed NSAIDS. Coverage limit: The maximum daily dose of celecoxib which will be reimbursed for the treatment of osteoarthritis is 200mg. Coverage limit: LU Authorization Period: 1 year Coverage limit: Rheumatoid arthritis Reason for Use code 317 For patients who have had: Coverage limit: History of a documented, clinically significant ulcer or GI bleed; or Failure or intolerance to at least three listed NSAIDS. Coverage limit: The maximum daily dose of celecoxib which will be reimbursed for the treatment of rheumatoid arthritis is 400mg. Coverage limit: LU Authorization Period: 1 year
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Celecoxib · DIN 02436302 Manufacturer: Sanis Health Inc.; listing date 2021-03-29 Health Canada: Marketed since 2021-02-02 · brand CELECOXIB · ATC M01AH01 CELECOXIB · form Capsule · route Oral · ingredients CELECOXIB 200 MG · company Sanis health inc · schedule Prescription
Check this DIN again · Health Canada product record

Celecoxib: Formulary list price $0.2558/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.2558 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=92063 · Verify on the e-Formulary ↗ (DIN 02436302)

Source record
DIN 02436302: Celecoxib Raw flags: sec12=Y, sec3=Y Item: 280804076; group id 377; item number 0899; lccId 00064; manufacturer id SAI Source form: Cap; strength: 200mg Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below Source prices (unrounded): $0.2558; ministry $0.2558 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02436302 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=92063 Therapeutic Notes (formulary) NSAIDs have a high rate of serious adverse effects in the elderly. When prescribing NSAIDs, the minimal effective dose for the shortest period of time should be used. In nonspecific pain and/or osteoarthritis, in the absence of joint inflammation (swelling), acetaminophen is a better first choice for analgesia. The most effective treatment to prevent NSAID-gastritis is misoprostol; although H-2 antagonists, such as ranitidine or cimetidine, are commonly used, they are not as effective. NSAIDs can significantly aggravate hypertension and congestive heart failure; ASA in doses below 1 gram per day is a better choice than other NSAID options if anti-inflammatory effects are required in patients with these conditions. Low dose ASA has additional benefits for anti-platelet indications that are not provided by other NSAIDs, and should be given in preference or in addition to other NSAIDs for patients with vascular indications.
Interchangeable products
AG-Celecoxib · DIN 02437589 · $0.2558 Act Celecoxib · DIN 02420163 · $0.2558 Apo-Celecoxib · DIN 02418940 · $0.2558 Auro-Celecoxib · DIN 02445689 · $0.2558 Bio-Celecoxib · DIN 02426390 · $0.2558 Celebrex · DIN 02239942 · $0.2558 Celecoxib · DIN 02429683 · $0.2558 Jamp-Celecoxib · DIN 02424541 · $0.2558 M-Celecoxib · DIN 02495473 · $0.2558 Mar-Celecoxib · DIN 02420066 · $0.2558 Mint-Celecoxib · DIN 02412500 · $0.2558 NRA-Celecoxib · DIN 02479745 · $0.2558 PMS-Celecoxib · DIN 02355450 · $0.2558 PMSC-Celecoxib · DIN 02517124 · $0.2558 Ran-Celecoxib · DIN 02412381 · $0.2558 Sdz Celecoxib · DIN 02442647 · $0.2558 Teva-Celecoxib · DIN 02288923 · $0.2558
Shortage status: resolved shortage (ended 2021-05-05); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02436302
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Jamp-Celecoxib · DIN 02424541 · 200mg · capsule

Limited Use — Reason for Use code 316, 317 requiredMarketed · checked 2026-09-02
Write on scriptLU code 316, 317 (patient must meet the criteria below)
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Ontario Limited Use criteria — code 316, 317
Coverage limit: Osteoarthritis Reason for Use code 316 For patients who have failed an adequate trial of acetaminophen (e.g. acetaminophen 1g QID for several weeks) and have had: Coverage limit: History of a documented, clinically significant ulcer or GI bleed; or Failure or intolerance to at least three listed NSAIDS. Coverage limit: The maximum daily dose of celecoxib which will be reimbursed for the treatment of osteoarthritis is 200mg. Coverage limit: LU Authorization Period: 1 year Coverage limit: Rheumatoid arthritis Reason for Use code 317 For patients who have had: Coverage limit: History of a documented, clinically significant ulcer or GI bleed; or Failure or intolerance to at least three listed NSAIDS. Coverage limit: The maximum daily dose of celecoxib which will be reimbursed for the treatment of rheumatoid arthritis is 400mg. Coverage limit: LU Authorization Period: 1 year
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Jamp-Celecoxib · DIN 02424541 Manufacturer: Jamp Pharma Corporation; listing date 2015-01-28 Health Canada: Marketed since 2026-03-12 · brand JAMP CELECOXIB · ATC M01AH01 CELECOXIB · form Capsule · route Oral · ingredients CELECOXIB 200 MG · company Jamp pharma corporation · schedule Prescription
Check this DIN again · Health Canada product record

Jamp-Celecoxib: Formulary list price $0.2558/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.2558 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=90923 · Verify on the e-Formulary ↗ (DIN 02424541)

Source record
DIN 02424541: Jamp-Celecoxib Raw flags: sec12=Y, sec3=Y Item: 280804076; group id 377; item number 0899; lccId 00064; manufacturer id JPC Source form: Cap; strength: 200mg Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below Source prices (unrounded): $0.2558; ministry $0.2558 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02424541 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=90923 Therapeutic Notes (formulary) NSAIDs have a high rate of serious adverse effects in the elderly. When prescribing NSAIDs, the minimal effective dose for the shortest period of time should be used. In nonspecific pain and/or osteoarthritis, in the absence of joint inflammation (swelling), acetaminophen is a better first choice for analgesia. The most effective treatment to prevent NSAID-gastritis is misoprostol; although H-2 antagonists, such as ranitidine or cimetidine, are commonly used, they are not as effective. NSAIDs can significantly aggravate hypertension and congestive heart failure; ASA in doses below 1 gram per day is a better choice than other NSAID options if anti-inflammatory effects are required in patients with these conditions. Low dose ASA has additional benefits for anti-platelet indications that are not provided by other NSAIDs, and should be given in preference or in addition to other NSAIDs for patients with vascular indications.
Interchangeable products
AG-Celecoxib · DIN 02437589 · $0.2558 Act Celecoxib · DIN 02420163 · $0.2558 Apo-Celecoxib · DIN 02418940 · $0.2558 Auro-Celecoxib · DIN 02445689 · $0.2558 Bio-Celecoxib · DIN 02426390 · $0.2558 Celebrex · DIN 02239942 · $0.2558 Celecoxib · DIN 02429683 · $0.2558 Celecoxib · DIN 02436302 · $0.2558 M-Celecoxib · DIN 02495473 · $0.2558 Mar-Celecoxib · DIN 02420066 · $0.2558 Mint-Celecoxib · DIN 02412500 · $0.2558 NRA-Celecoxib · DIN 02479745 · $0.2558 PMS-Celecoxib · DIN 02355450 · $0.2558 PMSC-Celecoxib · DIN 02517124 · $0.2558 Ran-Celecoxib · DIN 02412381 · $0.2558 Sdz Celecoxib · DIN 02442647 · $0.2558 Teva-Celecoxib · DIN 02288923 · $0.2558
Shortage status: resolved shortage (ended 2023-11-15); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02424541
Shortage record checked 2026-09-13T08:10:21.292534+00:00

M-Celecoxib · DIN 02495473 · 200mg · capsule

Limited Use — Reason for Use code 316, 317 requiredMarketed · checked 2026-09-02
Write on scriptLU code 316, 317 (patient must meet the criteria below)
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Ontario Limited Use criteria — code 316, 317
Coverage limit: Osteoarthritis Reason for Use code 316 For patients who have failed an adequate trial of acetaminophen (e.g. acetaminophen 1g QID for several weeks) and have had: Coverage limit: History of a documented, clinically significant ulcer or GI bleed; or Failure or intolerance to at least three listed NSAIDS. Coverage limit: The maximum daily dose of celecoxib which will be reimbursed for the treatment of osteoarthritis is 200mg. Coverage limit: LU Authorization Period: 1 year Coverage limit: Rheumatoid arthritis Reason for Use code 317 For patients who have had: Coverage limit: History of a documented, clinically significant ulcer or GI bleed; or Failure or intolerance to at least three listed NSAIDS. Coverage limit: The maximum daily dose of celecoxib which will be reimbursed for the treatment of rheumatoid arthritis is 400mg. Coverage limit: LU Authorization Period: 1 year
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
M-Celecoxib · DIN 02495473 Manufacturer: Mantra Pharma Inc.; listing date 2021-10-29 Health Canada: Marketed since 2020-03-24 · brand M-CELECOXIB · ATC M01AH01 CELECOXIB · form Capsule · route Oral · ingredients CELECOXIB 200 MG · company Mantra pharma inc · schedule Prescription
Check this DIN again · Health Canada product record

M-Celecoxib: Formulary list price $0.2558/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.2558 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=98539 · Verify on the e-Formulary ↗ (DIN 02495473)

Source record
DIN 02495473: M-Celecoxib Raw flags: sec12=Y, sec3=Y Item: 280804076; group id 377; item number 0899; lccId 00064; manufacturer id MAT Source form: Cap; strength: 200mg Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below Source prices (unrounded): $0.2558; ministry $0.2558 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02495473 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=98539 Therapeutic Notes (formulary) NSAIDs have a high rate of serious adverse effects in the elderly. When prescribing NSAIDs, the minimal effective dose for the shortest period of time should be used. In nonspecific pain and/or osteoarthritis, in the absence of joint inflammation (swelling), acetaminophen is a better first choice for analgesia. The most effective treatment to prevent NSAID-gastritis is misoprostol; although H-2 antagonists, such as ranitidine or cimetidine, are commonly used, they are not as effective. NSAIDs can significantly aggravate hypertension and congestive heart failure; ASA in doses below 1 gram per day is a better choice than other NSAID options if anti-inflammatory effects are required in patients with these conditions. Low dose ASA has additional benefits for anti-platelet indications that are not provided by other NSAIDs, and should be given in preference or in addition to other NSAIDs for patients with vascular indications.
Interchangeable products
AG-Celecoxib · DIN 02437589 · $0.2558 Act Celecoxib · DIN 02420163 · $0.2558 Apo-Celecoxib · DIN 02418940 · $0.2558 Auro-Celecoxib · DIN 02445689 · $0.2558 Bio-Celecoxib · DIN 02426390 · $0.2558 Celebrex · DIN 02239942 · $0.2558 Celecoxib · DIN 02429683 · $0.2558 Celecoxib · DIN 02436302 · $0.2558 Jamp-Celecoxib · DIN 02424541 · $0.2558 Mar-Celecoxib · DIN 02420066 · $0.2558 Mint-Celecoxib · DIN 02412500 · $0.2558 NRA-Celecoxib · DIN 02479745 · $0.2558 PMS-Celecoxib · DIN 02355450 · $0.2558 PMSC-Celecoxib · DIN 02517124 · $0.2558 Ran-Celecoxib · DIN 02412381 · $0.2558 Sdz Celecoxib · DIN 02442647 · $0.2558 Teva-Celecoxib · DIN 02288923 · $0.2558
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02495473
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Mar-Celecoxib · DIN 02420066 · 200mg · capsule

Limited Use — Reason for Use code 316, 317 requiredMarketed · checked 2026-09-02
Write on scriptLU code 316, 317 (patient must meet the criteria below)
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Ontario Limited Use criteria — code 316, 317
Coverage limit: Osteoarthritis Reason for Use code 316 For patients who have failed an adequate trial of acetaminophen (e.g. acetaminophen 1g QID for several weeks) and have had: Coverage limit: History of a documented, clinically significant ulcer or GI bleed; or Failure or intolerance to at least three listed NSAIDS. Coverage limit: The maximum daily dose of celecoxib which will be reimbursed for the treatment of osteoarthritis is 200mg. Coverage limit: LU Authorization Period: 1 year Coverage limit: Rheumatoid arthritis Reason for Use code 317 For patients who have had: Coverage limit: History of a documented, clinically significant ulcer or GI bleed; or Failure or intolerance to at least three listed NSAIDS. Coverage limit: The maximum daily dose of celecoxib which will be reimbursed for the treatment of rheumatoid arthritis is 400mg. Coverage limit: LU Authorization Period: 1 year
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Mar-Celecoxib · DIN 02420066 Manufacturer: Marcan Pharmaceuticals Inc.; listing date 2015-01-28 Health Canada: Marketed since 2014-11-17 · brand MAR-CELECOXIB · ATC M01AH01 CELECOXIB · form Capsule · route Oral · ingredients CELECOXIB 200 MG · company Marcan pharmaceuticals inc · schedule Prescription
Check this DIN again · Health Canada product record

Mar-Celecoxib: Formulary list price $0.2558/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.2558 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=90467 · Verify on the e-Formulary ↗ (DIN 02420066)

Source record
DIN 02420066: Mar-Celecoxib Raw flags: sec12=Y, sec3=Y Item: 280804076; group id 377; item number 0899; lccId 00064; manufacturer id MAR Source form: Cap; strength: 200mg Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below Source prices (unrounded): $0.2558; ministry $0.2558 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02420066 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=90467 Therapeutic Notes (formulary) NSAIDs have a high rate of serious adverse effects in the elderly. When prescribing NSAIDs, the minimal effective dose for the shortest period of time should be used. In nonspecific pain and/or osteoarthritis, in the absence of joint inflammation (swelling), acetaminophen is a better first choice for analgesia. The most effective treatment to prevent NSAID-gastritis is misoprostol; although H-2 antagonists, such as ranitidine or cimetidine, are commonly used, they are not as effective. NSAIDs can significantly aggravate hypertension and congestive heart failure; ASA in doses below 1 gram per day is a better choice than other NSAID options if anti-inflammatory effects are required in patients with these conditions. Low dose ASA has additional benefits for anti-platelet indications that are not provided by other NSAIDs, and should be given in preference or in addition to other NSAIDs for patients with vascular indications.
Interchangeable products
AG-Celecoxib · DIN 02437589 · $0.2558 Act Celecoxib · DIN 02420163 · $0.2558 Apo-Celecoxib · DIN 02418940 · $0.2558 Auro-Celecoxib · DIN 02445689 · $0.2558 Bio-Celecoxib · DIN 02426390 · $0.2558 Celebrex · DIN 02239942 · $0.2558 Celecoxib · DIN 02429683 · $0.2558 Celecoxib · DIN 02436302 · $0.2558 Jamp-Celecoxib · DIN 02424541 · $0.2558 M-Celecoxib · DIN 02495473 · $0.2558 Mint-Celecoxib · DIN 02412500 · $0.2558 NRA-Celecoxib · DIN 02479745 · $0.2558 PMS-Celecoxib · DIN 02355450 · $0.2558 PMSC-Celecoxib · DIN 02517124 · $0.2558 Ran-Celecoxib · DIN 02412381 · $0.2558 Sdz Celecoxib · DIN 02442647 · $0.2558 Teva-Celecoxib · DIN 02288923 · $0.2558
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02420066
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Mint-Celecoxib · DIN 02412500 · 200mg · capsule

Limited Use — Reason for Use code 316, 317 requiredMarketed · checked 2026-09-02
Write on scriptLU code 316, 317 (patient must meet the criteria below)
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Ontario Limited Use criteria — code 316, 317
Coverage limit: Osteoarthritis Reason for Use code 316 For patients who have failed an adequate trial of acetaminophen (e.g. acetaminophen 1g QID for several weeks) and have had: Coverage limit: History of a documented, clinically significant ulcer or GI bleed; or Failure or intolerance to at least three listed NSAIDS. Coverage limit: The maximum daily dose of celecoxib which will be reimbursed for the treatment of osteoarthritis is 200mg. Coverage limit: LU Authorization Period: 1 year Coverage limit: Rheumatoid arthritis Reason for Use code 317 For patients who have had: Coverage limit: History of a documented, clinically significant ulcer or GI bleed; or Failure or intolerance to at least three listed NSAIDS. Coverage limit: The maximum daily dose of celecoxib which will be reimbursed for the treatment of rheumatoid arthritis is 400mg. Coverage limit: LU Authorization Period: 1 year
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Mint-Celecoxib · DIN 02412500 Manufacturer: Mint Pharmaceuticals Inc.; listing date 2015-01-28 Health Canada: Marketed since 2014-11-17 · brand MINT-CELECOXIB · ATC M01AH01 CELECOXIB · form Capsule · route Oral · ingredients CELECOXIB 200 MG · company Mint pharmaceuticals inc · schedule Prescription
Check this DIN again · Health Canada product record

Mint-Celecoxib: Formulary list price $0.2558/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.2558 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=89714 · Verify on the e-Formulary ↗ (DIN 02412500)

Source record
DIN 02412500: Mint-Celecoxib Raw flags: sec12=Y, sec3=Y Item: 280804076; group id 377; item number 0899; lccId 00064; manufacturer id MIN Source form: Cap; strength: 200mg Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below Source prices (unrounded): $0.2558; ministry $0.2558 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02412500 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=89714 Therapeutic Notes (formulary) NSAIDs have a high rate of serious adverse effects in the elderly. When prescribing NSAIDs, the minimal effective dose for the shortest period of time should be used. In nonspecific pain and/or osteoarthritis, in the absence of joint inflammation (swelling), acetaminophen is a better first choice for analgesia. The most effective treatment to prevent NSAID-gastritis is misoprostol; although H-2 antagonists, such as ranitidine or cimetidine, are commonly used, they are not as effective. NSAIDs can significantly aggravate hypertension and congestive heart failure; ASA in doses below 1 gram per day is a better choice than other NSAID options if anti-inflammatory effects are required in patients with these conditions. Low dose ASA has additional benefits for anti-platelet indications that are not provided by other NSAIDs, and should be given in preference or in addition to other NSAIDs for patients with vascular indications.
Interchangeable products
AG-Celecoxib · DIN 02437589 · $0.2558 Act Celecoxib · DIN 02420163 · $0.2558 Apo-Celecoxib · DIN 02418940 · $0.2558 Auro-Celecoxib · DIN 02445689 · $0.2558 Bio-Celecoxib · DIN 02426390 · $0.2558 Celebrex · DIN 02239942 · $0.2558 Celecoxib · DIN 02429683 · $0.2558 Celecoxib · DIN 02436302 · $0.2558 Jamp-Celecoxib · DIN 02424541 · $0.2558 M-Celecoxib · DIN 02495473 · $0.2558 Mar-Celecoxib · DIN 02420066 · $0.2558 NRA-Celecoxib · DIN 02479745 · $0.2558 PMS-Celecoxib · DIN 02355450 · $0.2558 PMSC-Celecoxib · DIN 02517124 · $0.2558 Ran-Celecoxib · DIN 02412381 · $0.2558 Sdz Celecoxib · DIN 02442647 · $0.2558 Teva-Celecoxib · DIN 02288923 · $0.2558
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02412500
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Other drugs in the same formulary class (28:08:04 Nonsteroidal Anti-Inflammatory Agents) and how they are covered

Matched class: 28:08:04 Nonsteroidal Anti-Inflammatory Agents

Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment. Covered without a code on the Ontario formulary: DICLOFENAC SODIUM & MISOPROSTOL Some products covered without a code (check the product listing): DICLOFENAC SODIUM, FLURBIPROFEN, IBUPROFEN, INDOMETHACIN, KETOPROFEN, MEFENAMIC ACID, MELOXICAM, NAPROXEN, PIROXICAM, SULINDAC, TIAPROFENIC ACID 28:08:04 Nonsteroidal Anti-Inflammatory Agents

DICLOFENAC SODIUM

· 19 products · Listed, not a benefit (3), General benefit (11), Off-Formulary Interchangeable, not an ODB benefit (5) · strengths: 25mg, 50mg, 75mg, 100mg, 1.5% W/W · Ent Tab, LA Tab, Sup, Top Sol

DICLOFENAC SODIUM & MISOPROSTOL

· 6 products · General benefit · strengths: 50mg & 200mcg, 75mg & 200mcg · Tab

FLURBIPROFEN

· 4 products · Listed, not a benefit (2), General benefit (2) · strengths: 50mg, 100mg · Tab

IBUPROFEN

· 11 products · Listed, not a benefit (3), General benefit (8) · strengths: 200mg, 300mg, 400mg, 600mg · Tab

INDOMETHACIN

· 10 products · Listed, not a benefit (4), General benefit (6) · strengths: 25mg, 50mg, 100mg · Cap, Sup

KETOPROFEN

· 9 products · General benefit (4), Listed, not a benefit (5) · strengths: 50mg, 100mg, 200mg · Cap, Ent Tab, LA Tab

MEFENAMIC ACID

· 2 products · Listed, not a benefit (1), General benefit (1) · strengths: 250mg · Cap

MELOXICAM

· 14 products · Listed, not a benefit (2), General benefit (12) · strengths: 7.5mg, 15mg · Tab

NAPROXEN

· 21 products · Off-Formulary Interchangeable, not an ODB benefit (9), General benefit (8), Listed, not a benefit (4) · strengths: 250mg, 375mg, 500mg, 25mg/mL, 125mg · Ent Tab, O/L, Tab

PIROXICAM

· 6 products · Listed, not a benefit (2), General benefit (4) · strengths: 10mg, 20mg · Cap

SULINDAC

· 4 products · Listed, not a benefit (2), General benefit (2) · strengths: 150mg, 200mg · Tab

TIAPROFENIC ACID

· 4 products · Listed, not a benefit (2), General benefit (2) · strengths: 200mg, 300mg · Tab Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26; class 28:08:04 and 6 more
Full class listing Related classes: 28:08:08 Opiate Agonists, 28:08:12 Opiate Partial Agonists, 28:08:92 Miscellaneous Analgesics and Antipyretics, 28:16:04 Antidepressants, 28:16:08 Tranquilizers, 28:16:12 Other Psychotropics, 28:36:08 Anticholinergic Agents, 28:36:20 Dopamine Receptor Agonists Same formulary class, not same indication: class membership alone does not establish equivalent uses.
Other drugs whose Health Canada label lists a similar indication: pain
From Health Canada product monographs; label wording only, not a treatment recommendation. Matching is lexical and uses one held product label per generic; formulations and qualifying criteria may differ. No displayed matched alternative is a general benefit. ACETAMINOPHEN & CAFFEINE & CODEINE PHOSPHATE · General benefit (2), Listed, not a benefit (2) INDICATIONS AND CLINICAL USE Adults TEVA-LENOLTEC No. 2 and No. 3 (acetaminophen, caffeine and codeine phosphate) are indicated for the short-term relief of mild to moderate pain. PM: https://pdf.hres.ca/dpd_pm/00065848.PDF; date July 15, 2014; DIN 00653241; fetched 2026-09-10 Product monograph BUTORPHANOL TARTRATE · Off-Formulary Interchangeable, not an ODB benefit 1 INDICATIONS Adults BUTORPHANOL Nasal Spray (butorphanol tartrate) is indicated for: • the relief of moderate to severe acute pain. PM: https://pdf.hres.ca/dpd_pm/00069311.PDF; date MAR 24, 2015; DIN 02242504; fetched 2026-09-10 Product monograph CODEINE SULFATE TRIHYDRATE & MONOHYDRATE · Limited Use, codes 201 1 Indications CODEINE CONTIN (codeine controlled release tablets) is indicated for the relief of mild to moderate pain in adults requiring the prolonged use of an opioid analgesic preparation. PM: https://pdf.hres.ca/dpd_pm/00078791.PDF; date 2025-03-04; DIN 02163748; fetched 2026-09-10 Product monograph HYDROMORPHONE HCL · General benefit (21), Listed, not a benefit (3), General benefit; DIN status E (meaning unconfirmed); confirm discontinuation/availability with Health Canada (4) 1 INDICATIONS DILAUDID® (HYDROmorphone hydrochloride) is indicated for the relief of moderate to severe pain in adults. 1.1 Pediatrics No data are available to Health Canada. PM: https://pdf.hres.ca/dpd_pm/00072218.PDF; date August 29, 2023; DIN 00125083; fetched 2026-09-10 Product monograph OXYCODONE HCL · Off-Formulary Interchangeable, not an ODB benefit 1 INDICATIONS Supeudol® 5 (oxycodone hydrochloride tablets) / Supeudol® 10 (oxycodone hydrochloride tablets) is indicated for: • relief of moderate to severe pain. PM: https://pdf.hres.ca/dpd_pm/00080231.PDF; date not captured; DIN 00443948; fetched 2026-09-10 Product monograph Coverage source: ON formulary extract 2026-08-26
What the Health Canada label says it is for
1 INDICATIONS CELEBREX (celecoxib capsules) is indicated for relief of symptoms associated with: • Osteoarthritis, • Adult Rheumatoid Arthritis, and • Ankylosing Spondylitis CELEBREX is also indicated for the short-term ( 7 days) management of moderate to severe acute pain in adults in conditions such as the following: • Musculoskeletal and/or soft tissue trauma including sprains, • Postoperative orthopaedic, and • Pain following dental extraction CELEBREX, particularly at doses higher than 200 mg per day, is associated with an increased risk of serious cardiovascular related adverse events (such as myocardial infarction, stroke or thrombotic events), which can be fatal. Doses of CELEBREX > 200 mg/day should NOT be used in patients with ischemic heart disease, cerebrovascular disease, patients with congestive heart failure (NYHA II-IV) or patients with risk factors for cardiovascular disease. For patients with an increased risk of developing cardiovascular adverse events, other management strategies that do NOT include the use of NSAIDs, particularly celecoxib, diclofenac, or ibuprofen, should be considered first (see 2 CONTRAINDICATIONS and 7 WARNINGS… https://pdf.hres.ca/dpd_pm/00080998.PDF PM date: 2025-07-09 Source product: CELEBREX; DIN 02239941; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.